Supernus Pharmaceuticals

Recent news

• Rating change
  Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $67
  Market Newswire · 2026/7/9
• Rating change
  Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $66
  Market Newswire · 2026/4/13
• Rating change
  Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $63
  Market Newswire · 2026/1/9
• Rating change
  Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $63
  Market Newswire · 2025/9/30
• Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $66
  Market Newswire · 2026/7/27
• Company notice
  Supernus Pharmaceuticals: Supernus Pharmaceuticals, Inc. - Anticipated Adjustment Option Symbol: SUPN New Symbol: SUPN1
  OCC · 2026/9/17
• Rating change
  TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $65
  Market Newswire · 2026/2/25
• Rating change
  TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $60
  Market Newswire · 2025/11/5
• Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, Vs. FactSet Est of $0.04 EPS
  MT Newswires · 2026/8/3
• Rating change
  Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55
  Market Newswire · 2026/5/7
• Rating change
  Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
  Market Newswire · 2026/1/28
• Rating change
  Piper Sandler Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $65
  Market Newswire · 2025/10/9
• BofA Securities Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $63
  Market Newswire · 2026/7/13
• Rating change
  Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $43
  Market Newswire · 2025/8/7
• Rating change
  BofA Securities Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
  Market Newswire · 2026/2/25
• Rating change
  Cantor Fitzgerald Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $42
  Market Newswire · 2025/7/30
• Rating change
  Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $55
  Market Newswire · 2025/12/19
• TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
  Market Newswire · 2026/8/4
• Rating change
  TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $60
  Market Newswire · 2025/10/23
• Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q2 Revenue $219.1M, Vs. FactSet Est of $205.3M
  MT Newswires · 2026/8/3

Headlines are aggregated automatically and are not independently verified or edited by our team.